IL12RB2 and neoplasm: To rule out the possibility that NHS–rmIL-12 directly alters the viability of MOC22 tumor cells in vivo, NHS–rmIL-12 treatment was performed in IL-12Rb2–KO mice bearing established MOC22 tumors.